Справка
x
Поиск
Закладки
Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Инфекционный эндокардит и инфекция внутрисердечных устройств
Список литературы
Поставить закладку
Ackah J.K. [et al.]. Antimicrobial prophylaxis in adult cardiac surgery in the United Kingdom and Republic of Ireland // Journal of infection prevention. 2021. № 2 (22). Р. 83–90.
Adam E.L. [et al.]. Case series of infective endocarditis caused by Granulicatella species // International Journal of Infectious Diseases. 2015. № 31 (31). P. 56–58.
Afonso L. [et al.]. Echocardiography in Infective Endocarditis: State of the Art // Current Cardiology Reports. 2017. Vol. 19. № 12. 1–13 p.
AGGARWAL N. [et al.]. Retrospective analysis of outcome of pregnancy in women with congenital heart disease: Single-centre experience from North India // Australian and New Zealand Journal of Obstetrics and Gynaecology. 2009. № 4 (49). P. 376–381.
Ahuja T., Fong K., Louie E. Combination antifungal therapy for treatment of Candida parapsilosis prosthetic valve endocarditis and utility of T2Candida Panel®: A case series // IDCases. 2019. (15). P. e00525.
Ainsworth B.E. [et al.]. 2011 Compendium of Physical Activities: a second update of codes and MET values. // undefined. 2011. № 8 (43). P. 1575–1581.
Akhyari P. [et al.]. Is simultaneous splenectomy an additive risk factor in surgical treatment for active endocarditis? // Langenbeck’s Archives of Surgery. 2012. № 8 (397). C. 1261–1266.
Aksoy O. [et al.]. Early Surgery in Patients with Infective Endocarditis: A Propensity Score Analysis // Clinical Infectious Diseases. 2007. № 3 (44). P. 364– 372.
Al-Omari A. [et al.]. Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review // BMC Infectious Diseases. 2014. № 1 (14). P. 140.
Alagna L. [et al.]. Repeat endocarditis: analysis of risk factors based on the International Collaboration on Endocarditis — Prospective Cohort Study // Clinical Microbiology and Infection. 2014. № 6 (20). P. 566–575.
Amat-Santos I.J. [et al.]. Infective Endocarditis After Transcatheter Aortic Valve Implantation // Circulation. 2015. № 18 (131). P. 1566–1574.
Ambrosioni J. [et al.]. The Changing Epidemiology of Infective Endocarditis in the Twenty-First Century // Current Infectious Disease Reports. 2017. № 5 (19). P. 21.
Anavekar N.S. [et al.]. Impact of Prior Antiplatelet Therapy on Risk of Embolism in Infective Endocarditis // Clinical Infectious Diseases. 2007. № 9 (44). P. 1180–1186.
Anguera I, Miro JM, Evangelista A, Cabell CH, San Roman JA V.I. [et al.]. Periannular complications in infective endocarditis involving native aortic valves. // Am J Cardiol . 2006. № 98. P. 1254–1260.
Anguera I. [et al.]. Aorto-cavitary fistulous tract formation in infective endocarditis: clinical and echocardiographic features of 76 cases and risk factors for mortality // European Heart Journal. 2005. № 3 (26). P. 288–297.
Anguera I. [et al.]. Periannular Complications in Infective Endocarditis Involving Native Aortic Valves // The American Journal of Cardiology. 2006. № 9 (98). P. 1254–1260.
Asgeirsson H., Thalme A., Weiland O. Low mortality but increasing incidence of Staphylococcus aureus endocarditis in people who inject drugs // Medicine. 2016. № 49 (95). P. e5617.
Baddour Correction // Circulation. 2005. № 15 (112). P. 2374–2374.
Baddour L.M. [et al.]. Nonvalvular Cardiovascular Device–Related Infections // Circulation. 2003. № 16 (108). P. 2015–2031.
Baddour L.M. [et al.]. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association // Circulation. 2015. Vol. 132. № 15. 1435–1486 p.
Bai A.D. [et al.]. Diagnostic Accuracy of Transthoracic Echocardiography for Infective Endocarditis Findings Using Transesophageal Echocardiography as the Reference Standard: A Meta-Analysis // Journal of the American Society of Echocardiography. 2017. № 7 (30). P. 639–646.e8.
Bartash R., Nori P. Beta-lactam combination therapy for the treatment of Staphylococcus aureus and Enterococcus species bacteremia: A summary and appraisal of the evidence // International Journal of Infectious Diseases. 2017. Vol. 63. 7–12 p.
Bell W.R. [et al.]. Trousseau’s syndrome. Devastating coagulopathy in the absence of heparin // The American Journal of Medicine. 1985. № 4 (79). P. 423– 430.
Benito N. Health Care — Associated Native Valve Endocarditis: Importance of Non-nosocomial Acquisition // Annals of Internal Medicine. 2009. № 9 (150). P. 586.
Bensimhon L. [et al.]. Whole body [18F]fluorodeoxyglucose positron emission tomography imaging for the diagnosis of pacemaker or implantable cardioverter defibrillator infection: a preliminary prospective study // Clinical Microbiology and Infection. 2011. № 6 (17). P. 836–844.
Berdejo J. [et al.]. Evaluation of Vegetation Size and Its Relationship With Embolism in Infective Endocarditis // Circulation: Cardiovascular Imaging. 2014. № 1 (7). P. 149–154.
BERRINGTON A. Treatment of endocarditis using moxifloxacin // International Journal of Medical Microbiology. 2001. № 3 (291). P. 237–239.
Bertaglia E. [et al.]. Antibiotic prophylaxis with a single dose of cefazolin during pacemaker implantation: Incidence of long-term infective complications // PACE — Pacing and Clinical Electrophysiology. 2006. № 1 (29). P. 29–33.
Bezerra L.S. [et al.]. Antifungal Efficacy of Amphotericin B in Candida Albicans Endocarditis Therapy: Systematic Review // Brazilian Journal of Cardiovascular Surgery. 2020. № AHEAD. P. 1–8.
Bockeria L.A. [et al.]. 18F-fluorodeoxyglucose PET/CT in diagnostics of infectice endocarditis in patients with implantable cardiac devices // The Bulletin of Bakoulev Center "Cardiovascular Diseases". 2019. № 6 (20). P. 498–508.
Bongiorni M.G. [et al.]. Intracardiac Echocardiography in Patients with Pacing and Defibrillating Leads: A Feasibility Study // Echocardiography. 2008. № 6 (25). P. 632–638.
Bonzi M. [et al.]. Diagnostic accuracy of transthoracic echocardiography to identify native valve infective endocarditis: a systematic review and meta-analysis // Internal and Emergency Medicine. 2018. Т. 13. № 6. 937–946 p.
BRAUN M.U. [et al.]. Percutaneous Lead Implantation Connected to an External Device in Stimulation-Dependent Patients with Systemic Infection — A Prospective and Controlled Study // Pacing and Clinical Electrophysiology. 2006. № 8 (29). P. 875–879.
Brett M.S. Emergence of a high-level cefotaxime-resistant Streptococcus pneumoniae strain in New Zealand // Journal of Medical Microbiology. 2001. № 2 (50). P. 173–176.
Brignardello-Petersen R. Antibiotic prophylaxis probably reduces the risk of developing bacteremia in patients at risk of developing infective endocarditis who are undergoing dental extractions // Journal of the American Dental Association. 2017. Vol. 148. № 11. e169 p.
Brown J.P. [et al.]. Effect of patient education in the management of coronary heart disease: a systematic review and meta-analysis of randomized controlled trials // European Journal of Preventive Cardiology. 2013. № 4 (20). P. 701–714.
Bruun N.E. [et al.]. Cardiac imaging in infectious endocarditis // European Heart Journal. 2014. № 10 (35). P. 624–632.
Busca-Arenzana C. [et al.]. Non-bacterial Thrombotic Endocarditis IntechOpen, 2019. 291–294 p.
Cahill T.J. [et al.]. Antibiotic prophylaxis for infective endocarditis: A systematic review and meta-Analysis // Heart. 2017. Vol. 103. № 12. 937–944 p.
Carbone A. [et al.]. Spondylitis: A frequent and severe complication of infective endocarditis // Archives of Cardiovascular Diseases Supplements. 2020. № 1 (12). P. 82.
Carozza A. [et al.]. Infective endocarditis in intravenous drug abusers: patterns of presentation and long-term outcomes of surgical treatment. // The Journal of heart valve disease. 2006. № 1 (15). P. 125–31.
Casalta J.-P. [et al.]. Treatment of Staphylococcus aureus endocarditis with high doses of trimethoprim/sulfamethoxazole and clindamycin—Preliminary report // International Journal of Antimicrobial Agents. 2013. № 2 (42). P. 190– 191.
Cecchi E. [et al.]. Are the Duke criteria really useful for the early bedside diagnosis of infective endocarditis? Results of a prospective multicenter trial // Italian heart journal : official journal of the Italian Federation of Cardiology. 2005.№ 1 (6). P. 41–8.
Chan K.-L. [et al.]. Effect of Long-Term Aspirin Use on Embolic Events in Infective Endocarditis // Clinical Infectious Diseases. 2008. № 1 (46). P. 37–41.
Chiang K.H. [et al.]. How long should prophylactic antibiotics be prescribed for permanent pacemaker implantations? one day versus three days // Acta Cardiologica Sinica. 2013. № 4 (29). P. 341–346.
Chirouze C. [et al.]. Prognostic Factors in 61 Cases of Staphylococcus aureus Prosthetic Valve Infective Endocarditis from the International Collaboration on Endocarditis Merged Database // Clinical Infectious Diseases. 2004. № 9 (38). P. 1323–1327.
Chirouze C. [et al.]. Impact of early valve surgery on outcome of staphylococcus aureus prosthetic valve infective endocarditis: Analysis in the international collaboration of endocarditis-prospective cohort study // Clinical Infectious Diseases. 2015. № 5 (60). P. 741–749.
Choi H.N. [et al.]. Prosthetic valve endocarditis caused by HACEK organisms: A case report and systematic review of the literature // Infection and Chemotherapy. 2017. № 4 (49). P. 282–285.
Chou Y.H. [et al.]. Splenic abscess: Sonographic diagnosis and percutaneous drainage or aspiration // Gastrointestinal Radiology. 1992. № 1 (17). P. 262–266.
Chu V.H. [et al.]. Association between surgical indications, operative risk, and clinical outcome in infective endocarditis a prospective study from the international collaboration on endocarditis // Circulation. 2015. № 2 (131). P. 131– 140.
Coburn B. [et al.]. Antimicrobial susceptibilities of clinical isolates of HACEK organisms // Antimicrobial Agents and Chemotherapy. 2013. № 4 (57). P. 1989– 1991.
Colen T.W. [et al.]. Radiologic manifestations of extra-cardiac complications of infective endocarditis // European Radiology. 2008. № 11 (18). P. 2433–2445.
Connolly D.L. [et al.]. A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis // Journal of the American College of Cardiology. 2004. № 6 (43). P. 1134–1135.
Cornely O.A. [et al.]. Caspofungin for the treatment of less common forms of invasive candidiasis // Journal of Antimicrobial Chemotherapy. 2007. № 2 (60). P. 363–369.
Corra U. [et al.]. Secondary prevention through cardiac rehabilitation: physical activity counselling and exercise training: Key components of the position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitat // European Heart Journal. 2010. № 16 (31). P. 1967–1974.
Cosgrove S.E. [et al.]. Initial Low Dose Gentamicin for Staphylococcus aureus Bacteremia and Endocarditis Is Nephrotoxic // Clinical Infectious Diseases. 2009. № 6 (48). P. 713–721.
Costa A. Da [et al.]. Antibiotic Prophylaxis for Permanent Pacemaker Implantation // Circulation. 1998. № 18 (97). P. 1796–1801.
Cremieux A.-C. [et al.]. Evaluation of Antibiotic Diffusion into Cardiac Vegetations by Quantitative Autoradiography // Journal of Infectious Diseases. 1989. № 5 (159). P. 938–944.
Cremieux A.C. [et al.]. Evaluation of Antibiotic Diffusion into Cardiac Vegetations by Quantitative Autoradiography // Journal of Infectious Diseases. 1989. № 5 (159). P. 938–944.
Dahl A. [et al.]. Enterococcus faecalis Infective Endocarditis // Circulation. 2013. № 17 (127). P. 1810–1817.
Dajani A.S. [et al.]. Prevention of bacterial endocarditis // Journal of Endodontics. 1991. № 4 (17). P. 169–173.
Dalal A. [et al.]. Intracardiac echocardiography in the detection of pacemaker lead endocarditis // Journal of the American Society of Echocardiography. 2002. № 9 (15). P. 1027–1028.
Das, MD M. [et al.]. INFECTIVE ENDOCARDITIS CAUSED BY HACEK MICROORGANISMS // Annual Review of Medicine. 1997. № 1 (48). P. 25–33.
David T.E. [et al.]. Surgical treatment of active infective endocarditis: A continued challenge // The Journal of Thoracic and Cardiovascular Surgery. 2007. № 1 (133). P. 144–149.
Davierwala P.M. [et al.]. The value of an "Endocarditis Team" // Annals of Cardiothoracic Surgery. 2019. № 6 (8). P. 621–629.
Deharo J.C. [et al.]. Pathways for training and accreditation for transvenous lead extraction: a European Heart Rhythm Association position paper [Europace 2012;14:124–134. doi:10.1093/europace/eur338] // Europace. 2012. № 4 (14). P. 460–460.
Delahaye F. [et al.]. Indications and optimal timing for surgery in infective endocarditis BMJ Publishing Group Ltd, 2004. 618–620 p.
Dellinger R.P. [et al.]. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012 // Intensive Care Medicine. 2013. № 2 (39). P. 165–228.
Dhand A. [et al.]. Use of Antistaphylococcal -Lactams to Increase Daptomycin Activity in Eradicating Persistent Bacteremia Due to Methicillin-Resistant Staphylococcus aureus: Role of Enhanced Daptomycin Binding // Clinical Infectious Diseases. 2011. № 2 (53). P. 158–163.
Dickerman S.A. [et al.]. The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: An analysis from the ICE Prospective Cohort Study (ICE-PCS) // American Heart Journal. 2007. № 6 (154). P. 1086–1094.
DiNubile M.J. Short-course antibiotic therapy for right-sided endocarditis caused by Staphylococcus aureus in injection drug users // Annals of Internal Medicine. 1994. Vol. 121. № 11. 873–876 p.
Ducruet A.F. [et al.]. Intracranial infectious aneurysms: a comprehensive review // Neurosurgical Review. 2010. № 1 (33). P. 37.
Durack D.T. [et al.]. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings // The American Journal of Medicine. 1994. № 3 (96). P. 200–209.
Durante-Mangoni E. [et al.]. Management of Gram-negative and fungal endocarditis // International Journal of Antimicrobial Agents. 2010. № SUPPL. 2 (36).
Dutta T. [et al.]. Yield of Transesophageal Echocardiography for Nonbacterial Thrombotic Endocarditis and Other Cardiac Sources of Embolism in Cancer Patients With Cerebral Ischemia // The American Journal of Cardiology. 2006. № 6 (97). P. 894–898.
Duval X. [et al.]. Estimated Risk of Endocarditis in Adults with Predisposing Cardiac Conditions Undergoing Dental Procedures With or Without Antibiotic Prophylaxis // Clinical Infectious Diseases. 2006. № 12 (42). P. e102–e107.
Duval X. Effect of Early Cerebral Magnetic Resonance Imaging on Clinical Decisions in Infective Endocarditis // Annals of Internal Medicine. 2010. № 8 (152). P. 497.
Entenza J.M. [et al.]. Efficacies of Moxifloxacin, Ciprofloxacin, and Vancomycin against Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus Expressing Various Degrees of Ciprofloxacin Resistance // Antimicrobial Agents and Chemotherapy. 2001. № 11 (45). P. 3076–3083.
Erba P.A. [et al.]. Added Value of 99mTc-HMPAO-Labeled Leukocyte SPECT/CT in the Characterization and Management of Patients with Infectious Endocarditis // Journal of Nuclear Medicine. 2012. № 8 (53). P. 1235–1243.
Erba P.A. [et al.]. Radiolabeled WBC Scintigraphy in the Diagnostic Workup of Patients With Suspected Device-Related Infections // JACC: Cardiovascular Imaging. 2013. № 10 (6). P. 1075–1086.
Erba P.A. [et al.]. Multimodality Imaging in Infective Endocarditis // Circulation. 2019. № 21 (140). P. 1753–1765.
Erdogan H.B. [et al.]. Endovascular treatment of intracerebral mycotic aneurysm before surgical treatment of infective endocarditis // Texas Heart Institute Journal. 2004. № 2 (31). P. 165–167.
Ertugrul Mercan M. [et al.]. Non-HACEK Gram-negative bacillus endocarditis // Medecine et Maladies Infectieuses. 2019. № 8 (49). P. 616–620.
Eudailey K. [et al.]. Aggressive infective endocarditis and the importance of early repeat echocardiographic imaging // The Journal of Thoracic and Cardiovascular Surgery. 2014. № 3 (147). P. e26–e28.
Fagman E. [et al.]. ECG-gated computed tomography: a new role for patients with suspected aortic prosthetic valve endocarditis // European Radiology. 2012. № 11 (22). P. 2407–2414.
Falcone M., Russo A., Venditti M. Optimizing antibiotic therapy of bacteremia and endocarditis due to staphylococci and enterococci: New insights and evidence from the literature // Journal of Infection and Chemotherapy. 2015. Vol. 21. № 5. 330–339 p.
Fernandez-Hidalgo N. [et al.]. Immediate and long-term outcome of left-sided infective endocarditis. A 12-year prospective study from a contemporary cohort in a referral hospital // Clinical Microbiology and Infection. 2012. № 12 (18). P. E522–E530.
Fernández Hidalgo N. [et al.]. Contemporary Epidemiology and Prognosis of Health Care–Associated Infective Endocarditis // Clinical Infectious Diseases. 2008. № 10 (47). P. 1287–1297.
Fernández Guerrero M.L. [et al.]. Infective endocarditis at autopsy: A review of pathologic manifestations and clinical correlates // Medicine. 2012. Vol. 91. № 3. 152–164 p.
Ferrari A. [et al.]. Colonoscopy is mandatory after Streptococcus bovis endocarditis: a lesson still not learned. Case report // World Journal of Surgical Oncology. 2008. № 1 (6). P. 49.
Ferro J.M., Fonseca A.C. Infective endocarditis 2014. 75–91 p.
Feuchtner G.M. [et al.]. Multislice Computed Tomography in Infective Endocarditis // Journal of the American College of Cardiology. 2009. № 5 (53). P. 436–444.
Fillâtre P. [et al.]. Determinants and consequences of positive valve culture when cardiac surgery is performed during the acute phase of infective endocarditis // European Journal of Clinical Microbiology and Infectious Diseases. 2020. № 4 (39). P. 629–635.
Fletcher G.F. [et al.]. Exercise standards for testing and training: a statement for healthcare professionals from the American Heart Association // Circulation. 2001. № 14 (104). P. 1694–1740.
Fletcher G.F. [et al.]. Exercise Standards for Testing and Training // Circulation. 2013. № 8 (128). P. 873–934.
Foley M. Cardiac disease. In: Dildy G, Belfort M, Saade G, Phelan J H.G., Clark S E. Critical care obstetrics, 4th ed. / H.G. Foley M. Cardiac disease. In: Dildy G, Belfort M, Saade G, Phelan J, E. Clark S, Oxford: Blackwell, 2004. 252– 274 p.
Fortun J. [et al.]. Right-sided endocarditis caused by Staphylococcus aureus in drug abusers // Antimicrobial Agents and Chemotherapy. 1995. № 2 (39). P. 525– 528.
Fortún J. [et al.]. Short‐Course Therapy for Right‐Side Endocarditis Due to Staphylococcus aureus in Drug Abusers: Cloxacillin versus Glycopeptides in Combination with Gentamicin // Clinical Infectious Diseases. 2001. № 1 (33). P. 120–125.
Fournier P. [et al.]. Comprehensive Diagnostic Strategy for Blood Culture– Negative Endocarditis: A Prospective Study of 819 New Cases // Clinical Infectious Diseases. 2010. № 2 (51). P. 131–140.
Fowler V.G. [et al.]. Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus // New England Journal of Medicine. 2006. № 7 (355). P. 653–665.
Francioli P. [et al.]. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks. Efficacy and outpatient treatment feasibility. // JAMA. 1992. № 2 (267). P. 264–7.
Francioli P. Treatment of Streptococcal Endocarditis With a Single Daily Dose of Ceftriaxone Sodium for 4 Weeks // JAMA. 1992. № 2 (267). P. 264.
Francioli P., Ruch W., Stamboulian D. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 Days: A prospective multicenter study // Clinical Infectious Diseases. 1995. № 6 (21). P. 1406–1410.
Gahide G. [et al.]. Preoperative Evaluation in Aortic Endocarditis: Findings on Cardiac CT // American Journal of Roentgenology. 2010. № 3 (194). P. 574– 578.
García-Cabrera E. [et al.]. Neurological Complications of Infective Endocarditis // Circulation. 2013. № 23 (127). P. 2272–2284.
Gardiner B.J. [et al.]. Hampered by historical paradigms--echinocandins and the treatment of Candida endocarditis // Mycoses. 2014. № 5 (57). P. 316–319.
Garrigós C. [et al.]. Fosfomycin-Daptomycin and Other Fosfomycin Combinations as Alternative Therapies in Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus // Antimicrobial Agents and Chemotherapy. 2013. № 1 (57). P. 606–610.
Gavalda J. [et al.]. Effect of Gentamicin Dosing Interval on Therapy of Viridans Streptococcal Experimental Endocarditis with Gentamicin plus Penicillin. 1995.
Geneva W.H.O. Global recommendations on physical activity for health / W.H.O. Geneva, 2010.
Georges H. [et al.]. Outcome and prognostic factors of patients with right- sided infective endocarditis requiring intensive care unit admission // BMC Infectious Diseases. 2018. № 1 (18). P. 85.
Giuliano S. [et al.]. Endocarditis caused by nutritionally variant streptococci: A case report and literature review // Infezioni in Medicina. 2012. № 2 (20). P. 67– 74.
Glenny A.-M. [et al.]. Antibiotics for the prophylaxis of bacterial endocarditis in dentistry // Cochrane Database of Systematic Reviews. 2013. № 10 (2013). P. CD003813.
Goddard A.J.P., Tan G., Becker J. Computed tomography angiography for the detection and characterization of intra-cranial aneurysms: Current status // Clinical Radiology. 2005. № 12 (60). P. 1221–1236.
Gomes Neto M. [et al.]. Pre- and postoperative inspiratory muscle training in patients undergoing cardiac surgery: systematic review and meta-analysis // Clinical Rehabilitation. 2017. № 4 (31). P. 454–464.
González I. [et al.]. Symptomatic Peripheral Mycotic Aneurysms Due to Infective Endocarditis // Medicine. 2014. № 1 (93). P. 42–52.
González Quintela A. [et al.]. Non-bacterial thrombotic endocarditis in cancer patients. // Acta cardiologica. 1991. № 1 (46). P. 1–9.
Gould F.K. [et al.]. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: A report of the working party of the british society for antimicrobial chemotherapy // Journal of Antimicrobial Chemotherapy. 2012. Vol. 67. № 2. 269–289 p.
Goulenok T. [et al.]. Infective Endocarditis with Symptomatic Cerebral Complications: Contribution of Cerebral Magnetic Resonance Imaging // Cerebrovascular Diseases. 2013. № 4 (35). P. 327–336.
Grammes J.A. [et al.]. Percutaneous Pacemaker and Implantable Cardioverter-Defibrillator Lead Extraction in 100 Patients With Intracardiac Vegetations Defined by Transesophageal Echocardiogram // Journal of the American College of Cardiology. 2010. № 9 (55). P. 886–894.
Grillo S. [et al.]. Impact of β-Lactam and Daptomycin Combination Therapy on Clinical Outcomes in Methicillin-susceptible Staphylococcus aureus Bacteremia: A Propensity Score–matched Analysis // Clinical Infectious Diseases. 2019. № 9 (69). P. 1480–1488.
Grob A. [et al.]. Cardiac multidetector computed tomography in infective endocarditis: a pictorial essay // Insights into Imaging. 2014. Vol. 5. № 5. 559–570 с.
Guleri A. [et al.]. Daptomycin for the Treatment of Infective Endocarditis: Results from European Cubicin® Outcomes Registry and Experience (EU-CORE) // Infectious Diseases and Therapy. 2015. № 3 (4). P. 283–296.
Habib A. [et al.]. Impact of prior aspirin therapy on clinical manifestations of cardiovascular implantable electronic device infections // Europace. 2013. № 2 (15). P. 227–235.
Habib G. [et al.]. Value and limitations of the duke criteria for the diagnosis of infective endocarditis // Journal of the American College of Cardiology. 1999. № 7 (33). P. 2023–2029.
Habib G. [et al.]. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): The Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC) // European Heart Journal. 2009. № 19 (30). P. 2369–2413.
Habib G. [et al.]. Recommendations for the practice of echocardiography in infective endocarditis // European Journal of Echocardiography. 2010. № 2 (11). P. 202–219.
Habib G. [et al.]. 2015 ESC Guidelines for the management of infective endocarditis // European Heart Journal. 2015. № 44 (36). P. 3075–3128.
Habib G. [et al.]. The ESC-EORP EURO-ENDO (European Infective Endocarditis) registry // European Heart Journal — Quality of Care and Clinical Outcomes. 2019. № 3 (5). P. 202–207.
Habib G. [et al.]. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study // European Heart Journal. 2019. № 39 (40). P. 3222–3232.
Hagl C. [et al.]. Replacing the ascending aorta and aortic valve for acute prosthetic valve endocarditis: is using prosthetic material contraindicated? // The Annals of Thoracic Surgery. 2002. № 5 (74). P. S1781–S1785.
Hansen D. [et al.]. The European Association of Preventive Cardiology Exercise Prescription in Everyday Practice and Rehabilitative Training (EXPERT) tool: A digital training and decision support system for optimized exercise prescription in cardiovascular disease. Concept, definitions and construction methodology // European journal of preventive cardiology. 2017. № 10 (24). P. 1017–1031.
Hecht S.R., Berger M. Right-sided endocarditis in intravenous drug users. Prognostic features in 102 episodes // Annals of Internal Medicine. 1992. № 7 (117). P. 560–566.
Hess A. [et al.]. Brain MRI Findings in Neurologically Asymptomatic Patients with Infective Endocarditis // American Journal of Neuroradiology. 2013. № 8 (34). P. 1579–1584.
Hill E.E. [et al.]. Abscess in infective endocarditis: The value of transesophageal echocardiography and outcome // American Heart Journal. 2007. № 5 (154). P. 923–928.
Hill E.E. [et al.]. Management of Prosthetic Valve Infective Endocarditis // The American Journal of Cardiology. 2008. № 8 (101). P. 1174–1178.
Horstkotte D. Guidelines on Prevention, Diagnosis and Treatment of Infective Endocarditis Executive Summary The Task Force on Infective Endocarditis of the European Society of Cardiology // European Heart Journal. 2004. № 3 (25). P. 267–276.
Hosono M. [et al.]. Considerations in timing of surgical intervention for infective endocarditis with cerebrovascular complications // Journal of Heart Valve Disease. 2010. № 3 (19). P. 321–325.
Houard V. [et al.]. Prognostic value of residual vegetation after antibiotic treatment for infective endocarditis: A retrospective cohort study // International Journal of Infectious Diseases. 2020. (94). P. 34–40.
Hubert S. [et al.]. Prediction of Symptomatic Embolism in Infective Endocarditis // Journal of the American College of Cardiology. 2013. № 15 (62). P. 1384–1392.
Hui F.K. [et al.]. Mycotic aneurysm detection rates with cerebral angiography in patients with infective endocarditis // Journal of NeuroInterventional Surgery. 2015. № 6 (7). P. 449–452.
Hussain S.T. [et al.]. Tricuspid valve endocarditis // Annals of Cardiothoracic Surgery. 2017. № 3 (6). P. 255–261.
Hussein A.A. [et al.]. Microbiology of Cardiac Implantable Electronic Device Infections // JACC: Clinical Electrophysiology. 2016. № 4 (2). P. 498–505.
Incani A. [et al.]. Staphylococcus aureus bacteraemia: evaluation of the role of transoesophageal echocardiography in identifying clinically unsuspected endocarditis // European Journal of Clinical Microbiology & Infectious Diseases. 2013. № 8 (32). P. 1003–1008.
Irtyuga O.B. [et al.]. Detection rate and clinical significance of latent infective endocarditis in patients with aortic stenosis // Russian Journal of Cardiology. 2019. № 11. P. 10–15.
Isaacs D. Antibiotic prophylaxis for infective endocarditis: A systematic review and meta-analysis // Journal of Paediatrics and Child Health. 2017. Vol. 53. № 9. 921–922 p.
Iung B. [et al.]. Determinants of Cerebral Lesions in Endocarditis on Systematic Cerebral Magnetic Resonance Imaging // Stroke. 2013. № 11 (44). P. 3056–3062.
Iversen K. [et al.]. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis // New England Journal of Medicine. 2019. № 5 (380). P. 415–424.
Jang H. [et al.]. Salvage Treatment for Persistent Methicillin‐Resistant Staphylococcus aureus Bacteremia: Efficacy of Linezolid With or Without Carbapenem // Clinical Infectious Diseases. 2009. № 3 (49). P. 395–401.
Kahveci G. [et al.]. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Active Infective Endocarditis // American Journal of Cardiology. 2007. № 10 (99). P. 1429–1433.
Kaminsky L.A. [et al.]. Assessing Physical Activity as a Core Component in Cardiac Rehabilitation: A POSITION STATEMENT OF THE AMERICAN ASSOCIATION OF CARDIOVASCULAR AND PULMONARY REHABILITATION // Journal of cardiopulmonary rehabilitation and prevention. 2016. № 4 (36). P. 217–226.
Kang D.-H. [et al.]. Early Surgery versus Conventional Treatment for Infective Endocarditis // New England Journal of Medicine. 2012. № 26 (366). P. 2466–2473.
KARVONEN M.J., KENTALA E., MUSTALA O. The effects of training on heart rate; a longitudinal study // Annales medicinae experimentalis et biologiae Fenniae. 1957. № 3 (35). P. 307–315.
Kawata H. [et al.]. Utility and safety of temporary pacing using active fixation leads and externalized re-usable permanent pacemakers after lead extraction // Europace. 2013. № 9 (15). P. 1287–1291.
Kebar Y.M. [et al.]. Libman-Sacks endocarditis in patients with systemic lupus erythematosus with secondary antiphospholipid syndrome // Caspian Journal of Internal Medicine. 2019. № 3 (10). P. 339–342.
Kerchove L. de [et al.]. Reconstructive surgery in active mitral valve endocarditis: feasibility, safety and durability // European Journal of Cardio- Thoracic Surgery. 2007. № 4 (31). P. 592–599.
Kiefer T. [et al.]. Association Between Valvular Surgery and Mortality Among Patients With Infective Endocarditis Complicated by Heart Failure // JAMA. 2011. № 20 (306).
Kircher M., Lapa C. Novel Noninvasive Nuclear Medicine Imaging Techniques for Cardiac Inflammation // Current Cardiovascular Imaging Reports. 2017. Vol. 10. № 2.
Klug D. [et al.]. Systemic Infection Related to Endocarditis on Pacemaker Leads // Circulation. 1997. № 8 (95). P. 2098–2107.
Klug D. [et al.]. Risk Factors Related to Infections of Implanted Pacemakers and Cardioverter-Defibrillators // Circulation. 2007. № 12 (116). P. 1349–1355.
Knoll B. [et al.]. Infective Endocarditis Due to Penicillin-Resistant Viridans Group Streptococci // Clinical Infectious Diseases. 2007. № 12 (44). P. 1585– 1592.
KORNBERGER A. [et al.]. Bridge to Recovery or Permanent System Implantation: An Eight-Year Single-Center Experience in Transvenous Semipermanent Pacing // Pacing and Clinical Electrophysiology. 2013. № 9 (36). P. 1096–1103.
Koslow M. [et al.]. The Unique Clinical Features and Outcome of Infectious Endocarditis and Vertebral Osteomyelitis Co-infection // The American Journal of Medicine. 2014. № 7 (127). P. 669.e9-669.e15.
Kotova E.O. [et al.]. Infective endocarditis: Importance of molecular biological techniques in etiological diagnosis // Terapevticheskii arkhiv. 2016. № 11 (88). P. 62–67.
Kotova E.O. [et al.]. Infective Endocarditis with Unknown Etiology: Possibilities of Conquering and Role of Microbiologistics // Kardiologiia. 2021. № 1 (61). P. 87–97.
Kuijpers J.M. [et al.]. Incidence, risk factors, and predictors of infective endocarditis in adult congenital heart disease: Focus on the use of prosthetic material // European Heart Journal. 2017. № 26 (38). P. 2048–2056.
Kupferwasser L.I. [et al.]. Acetylsalicylic Acid Reduces Vegetation Bacterial Density, Hematogenous Bacterial Dissemination, and Frequency of Embolic Events in Experimental Staphylococcus aureus Endocarditis Through Antiplatelet and Antibacterial Effects // Circulation. 1999. № 21 (99). P. 2791–2797.
Kusumoto F.M. [et al.]. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction // Heart Rhythm. 2017. № 12 (14). P. e503–e551.
LACASSIN F. [et al.]. Procedures associated with infective endocarditis in adults // European Heart Journal. 1995. № 12 (16). P. 1968–1974.
Lamas C.C. [et al.]. Diagnosis of blood culture-negative endocarditis and clinical comparison between blood culture-negative and blood culture-positive cases // Infection. 2016. № 4 (44). P. 459–466.
Lamy B. [et al.]. How to Optimize the Use of Blood Cultures for the Diagnosis of Bloodstream Infections? A State-of-the Art // Frontiers in Microbiology. 2016. № MAY (7). P. 697.
Landoni G. [et al.]. Volatile Anesthetics versus Total Intravenous Anesthesia for Cardiac Surgery // New England Journal of Medicine. 2019. № 13 (380).
Lebeaux D. [et al.]. Aminoglycosides for infective endocarditis: time to say goodbye? // Clinical Microbiology and Infection. 2020. Vol. 26. № 6. 723–728 p.
Lee M.-R. [et al.]. Clinical Features of Right-Sided Infective Endocarditis Occurring in Non-Drug Users // Journal of Korean Medical Science. 2014. № 6 (29). P. 776.
Lee S.J. [et al.]. The Clinical Impacts of Apparent Embolic Event and the Predictors of In-Hospital Mortality in Patients with Infective Endocarditis // Journal of Korean Medical Science. 2014. № 12 (29). P. 1646.
Lennard K. [et al.]. Potential benefit of combination antifungal therapy in Aspergillus endocarditis // BMJ Case Reports. 2020. № 6 (13). P. e234008.
Lewis P.J. [et al.]. Teicoplanin in endocarditis: A multicentre, open european study // Chemotherapy. 1995. № 5 (41). P. 399–411.
Li J.S. [et al.]. Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis // Clinical Infectious Diseases. 2000. № 4 (30). P. 633– 638.
Liesenborghs L. [et al.]. Coagulation: At the heart of infective endocarditis // Journal of Thrombosis and Haemostasis. 2020. № 5 (18). P. 995–1008.
Liesman R.M. [et al.]. Laboratory Diagnosis of Infective Endocarditis // Journal of Clinical Microbiology. 2017. № 9 (55). P. 2599–2608.
Lisnevskaia L., Murphy G., Isenberg D. Systemic lupus erythematosus Lancet Publishing Group, 2014. 1878–1888 p.
Lockhart P.B. [et al.]. Bacteremia Associated With Toothbrushing and Dental Extraction // Circulation. 2008. № 24 (117). P. 3118–3125.
Lodise T.P. [et al.]. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin- susceptible Staphylococcus aureus // Antimicrobial Agents and Chemotherapy. 2007. № 10 (51). P. 3731–3733.
Lopes S. [et al.]. Allograft aortic root replacement in complex prosthetic endocarditis☆ // European Journal of Cardio-Thoracic Surgery. 2007. № 1 (32). P. 126–130.
Lopez J. [et al.]. Definition, clinical profile, microbiological spectrum, and prognostic factors of early-onset prosthetic valve endocarditis // European Heart Journal. 2007. № 6 (28). P. 760–765.
López J. [et al.]. Prognostic role of persistent positive blood cultures after initiation of antibiotic therapy in left-sided infective endocarditis // European Heart Journal. 2013. № 23 (34). P. 1749–1754.
Loyens M. [et al.]. Link between endocarditis on porcine bioprosthetic valves and allergy to pork // International Journal of Cardiology. 2013. № 2 (167). P. 600–602.
Lye D.C.B. [et al.]. Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review // European Journal of Clinical Microbiology & Infectious Diseases. 2005. № 11 (24). P. 753–755.
M. B. [et al.]. A review of combination antimicrobial therapy for enterococcus faecalis bloodstream infections and infective endocarditis // Clinical Infectious Diseases. 2018. Т. 67. № 2. 303–309 с.
Mahmood M. [et al.]. Meta-analysis of 18F-FDG PET/CT in the diagnosis of infective endocarditis // Journal of Nuclear Cardiology. 2019. № 3 (26). P. 922– 935.
Majumdar A. [et al.]. Renal pathological findings in infective endocarditis. // Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association — European Renal Association. 2000. № 11 (15). P. 1782–7.
Mantovani F. [et al.]. A first described case of cancer-associated non-bacterial thrombotic endocarditis in the era of direct oral anticoagulants // Thrombosis Research. 2017. Vol. 149. 45–47 p.
Marmelo F., Rocha V., Moreira-Gonçalves D. The impact of prehabilitation on post-surgical complications in patients undergoing non-urgent cardiovascular surgical intervention: Systematic review and meta-analysis // European Journal of Preventive Cardiology. 2018. № 4 (25). P. 404–417.
Martí-Carvajal A.J. [et al.]. A comparison of different antibiotic regimens for the treatment of infective endocarditis // Cochrane Database of Systematic Reviews. 2020. Vol. 2020. № 5.
Martín-Dávila P. [et al.]. Analysis of mortality and risk factors associated with native valve endocarditis in drug users: The importance of vegetation size // American Heart Journal. 2005. № 5 (150). P. 1099–1106.
Martínez E. [et al.]. Effect of Penicillin Resistance of Streptococcus pneumoniae on the Presentation, Prognosis, and Treatment of Pneumococcal Endocarditis in Adults // Clinical Infectious Diseases. 2002. № 2 (35). P. 130–139.
Martino P. [et al.]. Teicoplanin in the treatment of gram-positive-bacterial endocarditis // Antimicrobial Agents and Chemotherapy. 1989. № 8 (33). P. 1329– 1334.
Mazibuko B., Ramnarain H., Moodley J. An audit of pregnant women with prosthetic heart valves at a tertiary hospital in South Africa // Cardiovascular Journal of Africa. 2012. № 4 (23). P. 216–221.
McDonald J.R. Acute Infective Endocarditis // Infectious Disease Clinics of North America. 2009. Vol. 23. № 3. 643–664 p.
Meer J.T.M. van der [et al.]. Efficacy of antibiotic prophylaxis for prevention of native-valve endocarditis // The Lancet. 1992. № 8786 (339). P. 135–139.
Meier-Ewert H.K., Gray M.-E., John R.M. Endocardial pacemaker or defibrillator leads with infected vegetations: a single-center experience and consequences of transvenous extraction // American Heart Journal. 2003. № 2 (146). P. 339–344.
Mezzani A. [et al.]. Aerobic exercise intensity assessment and prescription in cardiac rehabilitation: a joint position statement of the European Association for Cardiovascular Prevention and Rehabilitation, the American Association of Cardiovascular and Pulmonary Rehabilitation and the Canadian Association of Cardiac Rehabilitation // European journal of preventive cardiology. 2013. № 3 (20). P. 442–467.
Mirabel M. [et al.]. Long-term outcomes and cardiac surgery in critically ill patients with infective endocarditis // European Heart Journal. 2014. № 18 (35). P. 1195–1204.
Miró J.M. [et al.]. Addition of Gentamicin or Rifampin Does Not Enhance the Effectiveness of Daptomycin in Treatment of Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus // Antimicrobial Agents and Chemotherapy. 2009. № 10 (53). P. 4172–4177.
Miró J.M. [et al.]. High-Dose Daptomycin plus Fosfomycin Is Safe and Effective in Treating Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Endocarditis // Antimicrobial Agents and Chemotherapy. 2012. № 8 (56). P. 4511–4515.
Miro J.M., Pericas J.M., Rio A. Del A new era for treating enterococcus faecalis endocarditis ampicillin plus short-course gentamicin or ampicillin plus ceftriaxone: That is the question! // Circulation. 2013. Vol. 127. № 17. 1763–1766 p.
Mohananey D. [et al.]. Association of vegetation size with embolic risk in patients with infective endocarditis a systematic review and meta-analysis // JAMA Internal Medicine. 2018. Vol. 178. № 4. 502–510 p.
Moiseev V.S. [et al.]. Infective Endocarditis in Moscow General Hospital: Clinical Characteristics and Outcomes (Single-Center 7 Years’ Experience) // Kardiologiia. 2018. № 12 (58). P. 66–75.
Montoya M.E., Karnath B.M., Ahmad M. Endocarditis during Pregnancy // Southern Medical Journal. 2003. № 11 (96). P. 1156–1157.
Moons P. What do adult patients with congenital heart disease know about their disease, treatment, and prevention of complications? A call for structured patient education // Heart. 2001. № 1 (86). P. 74–80.
Moore B. [et al.]. Incidence, predictors and outcomes of infective endocarditis in a contemporary adult congenital heart disease population // International Journal of Cardiology. 2017. (249). P. 161–165.
Mora S. [et al.]. Physical Activity and Reduced Risk of Cardiovascular Events // Circulation. 2007. № 19 (116). P. 2110–2118.
Morissens M, Viart P, Tecco L, Wauthy P, Michiels S, Dessy H, Malekzadeh MS, Verbeet T C.R. Does congenital heart disease severely jeopardise family life and pregnancies? Obstetrical history of women with congenital heart disease in a single tertiary centre. // Cardiol Young . 2013. № 23. P. 41–46.
Morris N.A. [et al.]. Neurologic Complications in Infective Endocarditis: Identification, Management, and Impact on Cardiac Surgery // The Neurohospitalist. 2014. № 4 (4). P. 213–222.
Mügge A. [et al.]. Echocardiography in infective endocarditis: Reassessment of prognostic implications of vegetation size determined by the transthoracic and the transesophageal approach // Journal of the American College of Cardiology. 1989. № 3 (14). P. 631–638.
Murakami T. [et al.]. Factors associated with surgery for active endocarditis in congenital heart disease // International Journal of Cardiology. 2012. № 1 (157). P. 59–62.
Murashita T. Surgical Treatment for Tricuspid Valve Infective Endocarditis InTech, 2018.
Musci M. [et al.]. Homograft aortic root replacement in native or prosthetic active infective endocarditis: Twenty-year single-center experience // The Journal of Thoracic and Cardiovascular Surgery. 2010. № 3 (139). P. 665–673.
Nadji G. [et al.]. Heart failure in left-sided native valve infective endocarditis: characteristics, prognosis, and results of surgical treatment // European Journal of Heart Failure. 2009. № 7 (11). P. 668–675.
Najmeddin F., Khalili H. Comment on: Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy // Journal of Antimicrobial Chemotherapy. 2012. № 12 (67). P. 3016–3017.
Narducci M.L. [et al.]. Usefulness of Intracardiac Echocardiography for the Diagnosis of Cardiovascular Implantable Electronic Device–Related Endocarditis // Journal of the American College of Cardiology. 2013. № 13 (61). P. 1398–1405.
Nashef S.A.M. [et al.]. EuroSCORE II // European Journal of Cardio- Thoracic Surgery. 2012. № 4 (41). P. 734–745.
Nicolau D.P. [et al.]. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients // Antimicrobial Agents and Chemotherapy. 1995. № 3 (39). P. 650–655.
Nigo M. [et al.]. What’s New in the Treatment of Enterococcal Endocarditis? // Current Infectious Disease Reports. 2014. № 10 (16). P. 431.
Nishimura R.A. [et al.]. 2014 AHA/ACC guideline for the management of patients with valvular heart disease // The Journal of Thoracic and Cardiovascular Surgery. 2014. № 1 (148). P. e1–e132.
Niwa K. Infective endocarditis in congenital heart disease: Japanese national collaboration study // Heart. 2005. № 6 (91). P. 795–800.
Nordström L. [et al.]. Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? // Journal of Antimicrobial Chemotherapy. 1990. № 1 (25). P. 159–173.
Nunes M.C.P. [et al.]. Outcomes of infective endocarditis in the current era: Early predictors of a poor prognosis // International Journal of Infectious Diseases. 2018. (68). P. 102–107.
Olaison L., Schadewitz K. Enterococcal Endocarditis in Sweden, 1995–1999: Can Shorter Therapy with Aminoglycosides Be Used? // Clinical Infectious Diseases. 2002. № 2 (34). P. 159–166.
Ong E. [et al.]. Thrombolysis for stroke caused by infective endocarditis: an illustrative case and review of the literature // Journal of Neurology. 2013. № 5 (260). P. 1339–1342.
Palestro C.J. [et al.]. Society of Nuclear Medicine Procedure Guideline for 99mTc-Exametazime (HMPAO)-Labeled Leukocyte Scintigraphy for Suspected Infection/Inflammation // Society of Nuclear Medicine Procedure Guidelines. 2004. P. 1–6.
Parra J.A. [et al.]. Detection of spleen, kidney and liver infarcts by abdominal computed tomography does not affect the outcome in patients with left-side infective endocarditis // Medicine (United States). 2018. № 33 (97). P. e11952.
Paturel L, Casalta JP, Habib G, Nezri M R.D. Actinobacillus actinomycetemcomitans Qeios, 2020. 98–118 p.
Pecha S. [et al.]. Transcutaneous lead implantation connected to an externalized pacemaker in patients with implantable cardiac defibrillator/pacemaker infection and pacemaker dependency // Europace. 2013. № 8 (15). P. 1205–1209.
Pericà s J.M. [et al.]. Outpatient Parenteral Antibiotic Treatment for Infective Endocarditis: A Prospective Cohort Study From the GAMES Cohort // Clinical Infectious Diseases. 2019. № 10 (69). P. 1690–1700.
Pericàs J.M. [et al.]. Efficacy and safety of fosfomycin plus imipenem versus vancomycin for complicated bacteraemia and endocarditis due to methicillin- resistant Staphylococcus aureus: a randomized clinical trial // Clinical Microbiology and Infection. 2018. Vol. 24. № 6. 673–676 p.
Périchon B., Courvalin P. Synergism between β-Lactams and Glycopeptides against VanA-Type Methicillin-Resistant Staphylococcus aureus and Heterologous Expression of the vanA Operon // Antimicrobial Agents and Chemotherapy. 2006. № 11 (50). P. 3622–3630.
Pettersson G.B. [et al.]. 2016 The American Association for Thoracic Surgery (AATS) consensus guidelines: Surgical treatment of infective endocarditis: Executive summary // Journal of Thoracic and Cardiovascular Surgery. 2017. № 6 (153). P. 1241–1258.e29.
Pfister R. [et al.]. Three-dimensional compared to two-dimensional transesophageal echocardiography for diagnosis of infective endocarditis // Infection. 2016. № 6 (44). P. 725–731.
Pichlmaier M. [et al.]. Complete removal as a routine treatment for any cardiovascular implantable electronic device–associated infection // The Journal of Thoracic and Cardiovascular Surgery. 2011. № 6 (142). P. 1482–1490.
Pigrau C. [et al.]. Spontaneous pyogenic vertebral osteomyelitis and endocarditis: Incidence, risk factors, and outcome // The American Journal of Medicine. 2005. № 11 (118). P. 1287.e17–1287.e24.
Piper C. The importance of secondary mitral valve involvement in primary aortic valve endocarditis. The mitral kissing vegetation // European Heart Journal. 2002. № 1 (23). P. 79–86.
Pontikis K. [et al.]. Efficacy of tigecycline alone and in combination with gentamicin in the treatment of experimental endocarditis due to linezolid-resistant Enterococcus faecium // Antimicrobial Agents and Chemotherapy. 2013. № 7 (57). P. 3392–3394.
Pulvirenti J.J. [et al.]. Infective endocarditis in injection drug users: Importance of human immunodeficiency virus serostatus and degree of immunosuppression // Clinical Infectious Diseases. 1996. № 1 (22). P. 40–45.
Purcell J.B. [et al.]. Relation of Troponin Elevation to Outcome in Patients With Infective Endocarditis // The American Journal of Cardiology. 2008. № 10 (101). P. 1479–1481.
Rajani R., Klein J.L. Infective endocarditis: A contemporary update // Clinical Medicine, Journal of the Royal College of Physicians of London. 2020. № 1 (20). P. 31–35.
Rasmussen R. V. [et al.]. Prevalence of infective endocarditis in patients with Staphylococcus aureus bacteraemia: the value of screening with echocardiography // European Journal of Echocardiography. 2011. № 6 (12). P. 414–420.
Rasmussen T. Health, recovery and rehabilitation after infective endocarditis 2015.
Rasmussen T.B. [et al.]. A randomised clinical trial of comprehensive cardiac rehabilitation versus usual care for patients treated for infective endocarditis-the CopenHeart IE trial protocol // BMJ Open. 2012. № 6 (2). P. 1929.
Raymond M. [et al.]. INFECTIVE ENDOCARDITIS IN PREGNANCY: A CONTEMPORARY COHORT // Journal of the American College of Cardiology. 2020. № 11 (75). P. 2145.
Regitz-Zagrosek V. [et al.]. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy // Kardiologia polska. 2019. № 3 (77). P. 245–326.
Reis L.J. [et al.]. Successful Treatment of Aspergillus Prosthetic Valve Endocarditis with Oral Voriconazole // Clinical Infectious Diseases. 2005. № 5 (41). P. 752–753.
Reyes H.A. [et al.]. Successful medical treatment of infective endocarditis caused by Candida parapsilosis in an immunocompromised patient // BMJ Case Reports. 2015. (2015).
Río A. del [et al.]. Surgical Treatment of Pacemaker and Defibrillator Lead Endocarditis // Chest. 2003. № 4 (124). P. 1451–1459.
Ritchie B.M. [et al.]. Risk factors for acute kidney injury associated with the treatment of bacterial endocarditis at a tertiary academic medical center // Journal of Chemotherapy. 2017. № 5 (29). P. 292–298.
Rodríguez-Sánchez B. [et al.]. Direct identification of pathogens from positive blood cultures using matrix-assisted laser desorption-ionization time-of- flight mass spectrometry // Clinical Microbiology and Infection. 2014. № 7 (20). P. O421–O427.
Roos-Hesselink J.W. [et al.]. Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology // European Heart Journal. 2013. № 9 (34). P. 657–665.
Rouzet F. [et al.]. Respective Performance of 18F-FDG PET and Radiolabeled Leukocyte Scintigraphy for the Diagnosis of Prosthetic Valve Endocarditis // Journal of Nuclear Medicine. 2014. № 12 (55). P. 1980–1985.
Rundström H. [et al.]. Pacemaker Endocarditis During 18 Years in Göteborg // Scandinavian Journal of Infectious Diseases. 2004. № 9 (36). P. 674–679.
Ruttmann E. [et al.]. Neurological Outcome of Septic Cardioembolic Stroke After Infective Endocarditis // Stroke. 2006. № 8 (37). P. 2094–2099.
Salvo G. Di Endocarditis in the elderly: clinical, echocardiographic, and prognostic features // European Heart Journal. 2003. № 17 (24). P. 1576–1583.
Sambola A. [et al.]. Streptococcus agalactiae Infective Endocarditis: Analysis of 30 Cases and Review of the Literature, 1962–1998 // Clinical Infectious Diseases. 2002. № 12 (34). P. 1576–1584.
Samuelson G. Global strategy on diet, physical activity and health // Scandinavian Journal of Nutrition. 2004. № 2 (48). P. 57–57.
San Román J.A. [et al.]. Prognostic Stratification of Patients with Left-Sided Endocarditis Determined at Admission // The American Journal of Medicine. 2007. № 4 (120). P. 369.e1–369.e7.
San Román J.A., Vilacosta I., López J. Comments on: ‘The infective endocarditis team: recommendations from an international working group’ // Heart. 2014. № 16 (100). P. 1301.2–1302.
Sanz M. [et al.]. Scientific evidence on the links between periodontal diseases and diabetes: Consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the International diabetes Federation and the European Federation of Periodontology // Diabetes Research and Clinical Practice. 2018. № 2 (137). P. 231–241.
Sarrazin J.-F. [et al.]. Usefulness of Fluorine-18 Positron Emission Tomography/Computed Tomography for Identification of Cardiovascular Implantable Electronic Device Infections // Journal of the American College of Cardiology. 2012. № 18 (59). P. 1616–1625.
Scola B. La, Raoult D. Direct Identification of Bacteria in Positive Blood Culture Bottles by Matrix-Assisted Laser Desorption Ionisation Time-of-Flight Mass Spectrometry // PLoS ONE. 2009. № 11 (4). P. e8041.
Selton-Suty C. [et al.]. Preeminence of Staphylococcus aureus in Infective Endocarditis: A 1-Year Population-Based Survey // Clinical Infectious Diseases. 2012. № 9 (54). P. 1230–1239.
Sexton D.J. [et al.]. Ceftriaxone Once Daily for Four Weeks Compared with Ceftriaxone Plus Gentamicin Once Daily for Two Weeks for Treatment of Endocarditis Due to Penicillin‐Susceptible Streptococci // Clinical Infectious Diseases. 1998. № 6 (27). P. 1470–1474.
Shakya S. [et al.]. Clinical Presentation of Infective Endocarditis in the Early 21st Century: A Descriptive Study // Open Forum Infectious Diseases. 2017. № suppl_1 (4). P. S559–S559.
Shapira Y. [et al.]. The impact of intraoperative transesophageal echocardiography in infective endocarditis // Israel Medical Association Journal. 2007. № 4 (9). P. 299–302.
Shapiro S., Kupferwasser L.I. Echocardiography predicts embolic events in infective endocarditis∗∗: Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Card // Journal of the American College of Cardiology. 2001. № 4 (37). P. 1077–1079.
Shaw E. [et al.]. Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: Protocol of a multicentre, randomised, phase III trial // BMJ Open. 2015. № 3 (5).
Siciliano R.F. [et al.]. Early-onset prosthetic valve endocarditis definition revisited: Prospective study and literature review // International Journal of Infectious Diseases. 2018. (67). P. 3–6.
Smith J.R. [et al.]. High-Dose Daptomycin Therapy for Staphylococcal Endocarditis and When to Apply It // Current Infectious Disease Reports. 2014. Vol. 16. № 10.
Snygg-Martin U, Rasmussen RV, Hassager C, Bruun NE, Andersson R O.L. The relationship between cerebrovascular complications and previously established use of antiplatelet therapy in left-sided infective endocarditis // Scand J Infect Dis . 2011. № 43. P. 899–904.
Sohail M.R. [et al.]. Management and Outcome of Permanent Pacemaker and Implantable Cardioverter-Defibrillator Infections // Journal of the American College of Cardiology. 2007. № 18 (49). P. 1851–1859.
Sohail M.R. [et al.]. Risk Factor Analysis of Permanent Pacemaker Infection // Clinical Infectious Diseases. 2007. № 2 (45). P. 166–173.
Sohail M.R. [et al.]. Infective Endocarditis Complicating Permanent Pacemaker and Implantable Cardioverter-Defibrillator Infection // Mayo Clinic Proceedings. 2008. № 1 (83). P. 46–53.
Sousa C. [et al.]. Infective endocarditis in intravenous drug abusers: an update // European Journal of Clinical Microbiology & Infectious Diseases. 2012. № 11 (31). P. 2905–2910.
Squires R.W. [et al.]. Progression of Exercise Training in Early Outpatient Cardiac Rehabilitation // Journal of Cardiopulmonary Rehabilitation and Prevention. 2018. № 3 (38). P. 139–146.
Stavi V. [et al.]. Comparison of Clinical Characteristics and Prognosis in Patients with Right- and Left-sided Infective Endocarditis // Rambam Maimonides Medical Journal. 2019. № 1 (10). P. e0003.
Steinbach W.J. [et al.]. A meta-analysis of medical versus surgical therapy for Candida endocarditis // Journal of Infection. 2005. № 3 (51). P. 230–247.
Stucki G. [et al.]. Rationale and principles of early rehabilitation care after an acute injury or illness // Disability and Rehabilitation. 2005. № 7–8 (27). P. 353– 359.
Taha L., Stegger M., Söderquist B. Staphylococcus lugdunensis: antimicrobial susceptibility and optimal treatment options // European Journal of Clinical Microbiology & Infectious Diseases. 2019. № 8 (38). P. 1449–1455.
Tam D.Y. [et al.]. Early vs Late Surgery for Patients With Endocarditis and Neurological Injury: A Systematic Review and Meta-analysis // Canadian Journal of Cardiology. 2018. Vol. 34. № 9. 1185–1199 p.
Tamura K. Clinical characteristics of infective endocarditis with vertebral osteomyelitis // Journal of Infection and Chemotherapy. 2010. № 4 (16). P. 260– 265.
Tarakji K.G. [et al.]. Cardiac implantable electronic device infections: Presentation, management, and patient outcomes // Heart Rhythm. 2010. № 8 (7). P. 1043–1047.
Tattevin P. [et al.]. Fungal endocarditis: current challenges // International Journal of Antimicrobial Agents. 2014. № 4 (44). P. 290–294.
Tattevin P. [et al.]. Update on blood culture-negative endocarditis // Médecine et Maladies Infectieuses. 2015. № 1–2 (45). P. 1–8.
Thornhill M.H. [et al.]. Quantifying infective endocarditis risk in patients with predisposing cardiac conditions // European Heart Journal. 2018. № 7 (39). P. 586– 595.
Thuny F. [et al.]. Risk of Embolism and Death in Infective Endocarditis: Prognostic Value of Echocardiography // Circulation. 2005. № 1 (112). P. 69–75.
Thuny F. [et al.]. Impact of cerebrovascular complications on mortality and neurologic outcome during infective endocarditis: a prospective multicentre study // European Heart Journal. 2007. № 9 (28). P. 1155–1161.
Thuny F. [et al.]. The timing of surgery influences mortality and morbidity in adults with severe complicated infective endocarditis: a propensity analysis // European Heart Journal. 2011. № 16 (32). P. 2027–2033.
Thuny F. [et al.]. Management of infective endocarditis: challenges and perspectives // The Lancet. 2012. № 9819 (379). P. 965–975.
Thuny F. [et al.]. Imaging investigations in infective endocarditis: Current approach and perspectives // Archives of Cardiovascular Diseases. 2013. № 1 (106). P. 52–62.
Tissot-Dupont H. [et al.]. High-dose trimethoprim-sulfamethoxazole and clindamycin for Staphylococcus aureus endocarditis // International Journal of Antimicrobial Agents. 2019. № 2 (54). P. 143–148.
Tornos P. [et al.]. Clinical Outcome and Long-Term Prognosis of Late Prosthetic Valve Endocarditis: A 20-Year Experience // Clinical Infectious Diseases. 1997. № 3 (24). P. 381–386.
Torres-Tortosa M. [et al.]. Prospective evaluation of a two-week course of intravenous antibiotics in intravenous drug addicts with infective endocarditis // European Journal of Clinical Microbiology & Infectious Diseases. 1994. № 7 (13). P. 559–564.
Truninger K. [et al.]. Long term follow up of prosthetic valve endocarditis: what characteristics identify patients who were treated successfully with antibiotics alone? // Heart. 1999. № 6 (82). P. 714–720.
Uranüs S., Alimoglu O. Splenic Abscess and Infarction — Rare Events for Which Surgery Is Mandatory // European Surgery. 2003. № 6 (35). P. 326–326.
Vahanian A. [et al.]. Guidelines on the management of valvular heart disease (version 2012) // European Heart Journal. 2012. № 19 (33). P. 2451–2496.
Veganzones J., Montero A., Maseda E. New evidence on the use of fosfomycin for bacteremia and infectious endocarditis // Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia. 2019. Vol. 32. № Suppl 1. 25–29 p.
Vieira M.L.C. Repeated echocardiographic examinations of patients with suspected infective endocarditis // Heart. 2004. № 9 (90). P. 1020–1024.
Vilacosta I. [et al.]. Risk of embolization after institution of antibiotic therapy for infective endocarditis // Journal of the American College of Cardiology. 2002. № 9 (39). P. 1489–1495.
Vind S.H., Hess S. Possible role of PET/CT in infective endocarditis // Journal of Nuclear Cardiology. 2010. № 3 (17). P. 516–519.
Viswanathan M. [et al.]. Interventions to Improve Adherence to Self- administered Medications for Chronic Diseases in the United States // Annals of Internal Medicine. 2012. № 11 (157). P. 785.
Waite I. [et al.]. Home-based preoperative rehabilitation (prehab) to improve physical function and reduce hospital length of stay for frail patients undergoing coronary artery bypass graft and valve surgery // Journal of Cardiothoracic Surgery. 2017. № 1 (12). P. 91.
Wang A. Contemporary Clinical Profile and Outcome of Prosthetic Valve Endocarditis // JAMA. 2007. № 12 (297). P. 1354.
Watkins R.R., Lemonovich T.L., File T.M. An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): Place in therapy // Core Evidence. 2012. Vol. 7. 131–143 p.
Wellens F. [et al.]. Prophylaxis in cardiac surgery. A controlled randomized comparison between cefazolin and cefuroxime // European journal of cardio- thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 1995. № 6 (9). P. 325–329.
White P.M. [et al.]. Intracranial Aneurysms: CT Angiography and MR Angiography for Detection—Prospective Blinded Comparison in a Large Patient Cohort // Radiology. 2001. № 3 (219). P. 739–749.
Wilkoff B.L. [et al.]. Transvenous Lead Extraction: Heart Rhythm Society Expert Consensus on Facilities, Training, Indications, and Patient Management // Heart Rhythm. 2009. № 7 (6). P. 1085–1104.
Wilson L.E. [et al.]. Prospective Study of Infective Endocarditis among Injection Drug Users // The Journal of Infectious Diseases. 2002. № 12 (185). P. 1761–1766.
Wilson W. [et al.]. Prevention of infective endocarditis: Guidelines from the American Heart Association // The Journal of the American Dental Association. 2007. № 6 (138). P. 739–760.
Wilson W.R. [et al.]. Prevention of Viridans Group Streptococcal Infective Endocarditis: A Scientific Statement from the American Heart Association // Circulation. 2021. (143). P. E963–E978.
Wojda T.R. [et al.]. Septic Embolism: A Potentially Devastating Complication of Infective Endocarditis InTech, 2016.
Yew H. Sen, Murdoch D.R. Global Trends in Infective Endocarditis Epidemiology // Current Infectious Disease Reports. 2012. № 4 (14). P. 367–372.
Yu C.H.Y., Minnema B.J., Gold W.L. Bacterial infections complicating tongue piercing // Canadian Journal of Infectious Diseases and Medical Microbiology. 2010. № 1 (21). P. e70–e74.
Yuan X.C. [et al.]. Diagnosis of infective endocarditis using echocardiography // Medicine (United States). 2019. № 38 (98).
Yung D. [et al.]. Antimicrobials for right-sided endocarditis in intravenous drug users: A systematic review // Journal of Antimicrobial Chemotherapy. 2007. Vol. 60. № 5. 921–928 p.
Zasowski E.J. [et al.]. Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections // Antimicrobial Agents and Chemotherapy. 2017. № 2 (61).
Алехин М.Н., Рыбакова М.К., Сидоренко Б.А. Б.О.М. Значение эхокардиографии в диагностике инфекционного эндокардита // Кардиология. 2005. № 6. C. 4–13.
Андреева Н. С., Реброва О. Ю. [и др.]. Системы оценки достоверности научных доказательств и убедительности рекомендаций: сравнительная характеристика и перспективы унификации // Медицинские технологии. Оценка и выбор. 2012. (4). C. 10–24.
Бокерия Л.А., Асланиди И.П., Пурсанова Д.М., Мухортова О.В., Шурупова И.В., Сергуладзе С.Ю. Диагностика электродного инфекционного эндокардита методом ПЭТ/КТ с 18F-фтордезоксиглюкозой // Анналы аритмологии. 2019. № 16. C. 1.
Данилов А.И., Козлов Р.С., Козлов С.Н. Практика проведения микробиологической диагностики инфекционного эндокардита в Российской Федерации // Вестник Смоленской государственной медицинской академии. 2019. № 1 (18). C. 90–94.
Демин А.А., Дробышева В.П. Инфекционный эндокардит внутривенных наркоманов // Клин. мед. 2000. № 8 (78). C. 47–51.
Демин А.А. Кардиология. Национальное руководство. (под ред. акад. Е.В. Шляхто). Гл. 19 «Инфекционный эндокардит». 3-е изд. М.: ГЭОТАР- Медиа, 2018. 816 с.(с. 597–616).
Муратов Р.М., Амирагов Р.И., Бабенко С.И. Инфекционный эндокардит (ИЭ) // Клинические рекомендации Министерства здравоохранения Российской Федерации. 2016. C. 50.
Николаевский Е.Н. Инфекционный эндокардит как медико-социальная проблема современной России // Новая наука: стратегии и векторы развития. 2016. № 88 (6–2). C. 26–29.
Поляков В.П., Николаевский Е.Н., Хубулава Г.Г., Шустов С.Б. Инфекционный эндокардит (современное состояние проблемы). Самара, 2007. 340 с.
Приказ Министерства здравоохранения РФ от 29 декабря 2012 г. № 1705н «О порядке организации медицинской реабилитации».
Рыбка М.М. Протоколы анестезиологического обеспечения рентгенэндоваскулярных и диагностических процедур, выполняемых у кардиохирургических пациентов различных возрастных групп. Методические рекомендации 2018.
Тюрин В.П. Инфекционные эндокардиты. М.: ГЭОТАР-Медиа, 2012. 242–243 c.
Федорова Т.А., Тазина С.Я., Семененко Н.А., Сотникова Т.И. Актуальные проблемы инфекционного эндокардита // Вестник Национального медико-хирургического центра им. Н.И. Пирогова. 2014. № 1. C. 125–127.
Шевченко Ю.Л. Инфекционный эндокардит. Руководство по кардиологии в четырех томах. Том 4: Заболевания сердечно-сосудистой системы (II): под ред. акад. Е.И.Чазова. М.: Практика, 2014. 453–495 c.
Федеральное агентство по техническому регулированию и метрологии. Национальный стандарт Российской Федерации. ГОСТР 52379–2005. Надлежащая клиническая практика. М., 2005.
Федеральная служба государственной статистики (Росстат) [Электронный ресурс]. URL:
www.gks.ru.
Эпидемиологический словарь, 4-е изд. под ред. Дж. М. Ласта для Международной эпидемиологической ассоциации. М., 2009. 316 с.
Для продолжения работы требуется
Registration
Предыдущая страница
Следующая страница
Table of contents
Список сокращений
Термины и определения
Инфекционный эндокардит и инфекция внутрисердечных устройств
+
Список литературы
Приложение А1. Состав рабочей группы по разработке и пересмотру клинических рекомендаций
Приложение А2. Методология разработки клинических рекомендаций
Приложение А3. Справочные материалы, включая соответствие показаний к применению и противопоказаний, способов применения и доз лекарственных препаратов, инструкции по применению лекарственного препарата
Приложение Б. Алгоритмы действий врача
+
Приложение В. Информация для пациента
Приложение Г1-ГN. Шкалы оценки, вопросники и другие оценочные инструменты состояния пациента, приведенные в клинических рекомендациях
+
Данный блок поддерживает скрол*